Načítá se...
Limitations of Anti-Angiogenic Treatment of Tumors
Clinical trials using anti-vascular endothelial growth factor /(VEGF) molecules induce a modest improvement in overall survival, measurable in weeks to just a few months, and tumors respond differently to these agents. In this review article, we have exposed some tumor characteristics and processes...
Uloženo v:
| Vydáno v: | Transl Oncol |
|---|---|
| Hlavní autoři: | , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Neoplasia Press
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6529826/ https://ncbi.nlm.nih.gov/pubmed/31121490 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.tranon.2019.04.022 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|